“We have been working towards a multi-indication PBS listing for nivolumab and ipilimumab with the PBAC since 2017. We have maintained momentum throughout this period as we have always understood the importance and impact of expedited access for Australian patients,” said Owen Smith, General Manager of Bristol Myers Squibb Australia and New Zealand. …
PBS listing expands access to immunotherapy for Australians with advanced cancer
March 1, 2026 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
PYC to present early polycystic kidney disease trial data at US nephrology conference
October 7, 2026 - - Australian Biotech -
CSL raises US$1.5 billion from US bond investors to refinance debt
October 7, 2026 - - Latest News -
Every serious attempt to reform PBS pricing has run into the same problem
October 7, 2026 - - Latest News -
AFT reaffirms profit guidance as its R&D pipeline moves toward 2029 launches
October 7, 2026 - - Latest News -
The patient who knows what they want is informed and not a danger
October 7, 2026 - - Latest News -
TGA turns to national security surveillance platform to police therapeutic goods compliance
October 6, 2026 - - Latest News -
Company size shapes CEO pay trends in Australian health care and biotechnology
October 6, 2026 - - Latest News